An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-Hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Hydroxyflutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors LIDDS
- 08 Feb 2018 According to a Lidds Pharma media release, results from this and the LPC-003 trials have been published in The Journal of Urology in December 2016.
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.